

AD _____

Award Number: W81XWH-12-1-0416

TITLE: Translational Studies of GALGT2 Gene Therapy for Duchenne Muscular Dystrophy

PRINCIPAL INVESTIGATOR: Paul T. Martin, PhD

CONTRACTING ORGANIZATION: The Research Institute at Nationwide Children's P[.] and
 Ô[] { à • ÉUPÁHGÉ

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE: ANNUAL		3. DATES COVERED 30 Sep 2013 – 29 Sep 2014	
4. TITLE AND SUBTITLE Translational Studies of GALGT2 Gene Therapy for Duchenne Muscular Dystrophy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0416	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Paul T. Martin, PhD Email: Paul.Martin@nationwidechildrens.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Research Institute at Nationwide Children's Hospital Columbus, OH 43205				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this proposal is to perform translational studies in support of developing GALGT2 gene therapy for use in Duchenne Muscular dystrophy patients. In year 2, we have completed Specific Aims 1 and 2 of the proposal, and now have begun the systemic delivery experiments described in Specific Aim 3. We now have completed the tasks of dosing all cohorts of experimental animals to be used in Years 1 and 2 (Wild type or WT, Cmah-/-, mdx and Cmah-/-mdx) via intramuscular injection with the two therapeutic gene therapy vectors to be tested (AAVrh74.MCK.GALGT2 and AAVrh74.MHCK7.GALGT2) and have analyzed all of the results from those experiments. This work demonstrates that Cmah-/- animals have more expression from rAAVrh74.(MCK or MHCK7).GALGT2 injection at the same dose compared to WT and that the human GALGT2 gene may show greater potency in DMD patients than its does in mdx mice due to the altered sialic acid repertoire that exists in humans. In addition, we show loss of GALGT2 expression in mdx muscles when injected at 2 weeks of age, likely the result of muscle damage prior to when GALGT2 expression would allow therapeutic effects. This stands in contrast to our studies showing robust inhibition of muscle damage when this vector is injected into adult mdx animals. We have done additional experiments to demonstrate that this lack of expression when vector is injected at two weeks in part is due to lack of time for GALGT2 overexpression to stabilize dystroglycan protein expression, as co-injection of dystroglycan cDNA with GALGT2 at 2 weeks of age allows for large scale GALGT2 overexpression using the same experimental paradigm. In summary, these studies suggest that use of the MHCK7 promoter in gene therapy vectors will be more potent in DMD patients, and that dystroglycan expression aids in GALGT2's therapeutic effects. Measures of mRNA and CT glycan expression also have defined the level of mRNA overexpression of GALGT2 required to saturate myofiber expression of functional CT glycan. Another major advance has occurred in the transition plan. We have now completed all in-life toxicology studies for use of rAAVrh74.MCK.GALGT2 and have now filed and obtained an IND its use in DMD patients from the FDA. Another major advance in the transition plan is that we have now begun cGMP manufacturing of rAAVrh74.MCK.GALGT2 for its potential use in the first ever DMD clinical trial.					
15. SUBJECT TERMS- Gene Therapy, Duchenne Muscular Dystrophy,					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	14	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

Front Cover	Page 1
Standard Form (SF) 298	Page 2
Table of Contents	Page 3
Introduction	Page 4
Body	Page 4
Key Research Accomplishments	Page 12
Reportable Outcomes	Page 13
Conclusion	Page 13
References	Page 14
Appendices	NA
Supporting Data	NA

Introduction:

GalgT2 overexpression in skeletal myofibers has been demonstrated to protect both wild type and dystrophic muscles from injury and to inhibit the development of muscular dystrophy in three mouse models of human disease, including the mdx mouse model of Duchenne Muscular Dystrophy (DMD)¹⁻⁵. We have developed two gene therapy vectors for use in human DMD clinical trials that allow expression of the human *GALGT2* gene driven by a skeletal muscle-specific promoter (AAV(rh.74)-MCK-*GALGT2*) or cardiac and skeletal muscle-specific promoter (AAV(rh.74)-MHCK7-*GALGT2*). Using these AAV8-like gene therapy vectors, which can cross the vascular barrier, we can effectively deliver *GALGT2* transgene to skeletal muscles via the bloodstream, providing functional correction in mdx mice¹. In order for such studies to have reference to clinical meaning in human trials, additional dose response studies will be done in this proposal using the mdx mouse and the more severe DMD-like *Cmah*^{-/-}mdx mouse, a mouse with a humanized sialoglycome⁶. The objective of the proposed work is to provide pre-clinical data in support of a planned IND application to use *GALGT2* gene therapy to treat Duchenne muscular dystrophy.

Body:

We have now completed milestones 1 and 2 (tasks 1-8), which is the entirety of the work proposed in Years 1 and 2 of the grant. In addition, we have begun milestone 3, which involves the experiments described in Year 3 (the forthcoming year of the proposal). Figure 1 shows dose response curves for intramuscular (IM) injection of rAAVrh74.MCK.GALGT2 and rAAVrh74.MHCK7.GALGT2 at doses of 1×10^{10} , 1×10^{11} and 5×10^{11} vector genomes (vg) in four different genotypes of mice, wild type (WT), *Cmah*^{-/-}, mdx and *Cmah*^{-/-}mdx. The percentage of myofibers overexpressing the CT carbohydrate, a functional readout of *GALGT2* overexpression, is shown. In each instance, mice were injected at 2-3 weeks of age and

analyzed at 3 months post-treatment. We have learned three important things from these studies. First, at the low dose shown (1×10^{10} vg), for both viral vectors, *Cmah^{-/-}* muscles showed increased percentages of transduced myofibers compared to WT muscles. Thus, GALGT2 overexpression is more potent, on a per dose basis, in mouse muscles with a humanized sialoglycome (*Cmah^{-/-}*) compared to wild type mouse muscles. Since GALGT2, as an enzyme, requires sialic acid on its substrates for its enzymatic activity⁷, these data suggest that human GALGT2 enzyme may be more potent at inducing muscle glycosylation when human sialic acids are present than when mouse sialic acids are present. This is a very encouraging finding as regards our previous definition of the minimally effective dose for functional muscle correction after rAAVrh74.MCK.GALGT2 treatment in mdx mouse muscle. The second thing we have learned is that the MHCK7 promoter is more potent at inducing GALGT2 glycosylation than the MCK promoter. At the 1×10^{10} vg dose, rAAVrh74.MHCK7.GALGT2 induced higher levels of muscle transduction in both WT and *Cmah^{-/-}* muscles than did rAAVrh74.MCK.GALGT2. This is in keeping with the original studies on this promoter that demonstrate that it is more effective than MCK in skeletal muscle⁸. Last, when injected at 2-3 weeks and analyzed 3 months later, both mdx and *Cmah^{-/-}*mdx muscles showed very poor levels of GALGT2 gene expression, suggesting that these transduced muscles were damaged prior to analysis. This stands in contrast to the clear effect of rAAVrh74.MCK.GALGT2 in protecting mdx muscles when injected into adult animals¹. We suggest that this is due to the fact that the majority of the TA and EDL muscle turns over in mdx mice between 3 and 6 weeks of age due to a severe bout of muscle damage. As rAAV vectors require 3 weeks to induce maximal gene expression, this likely means that the kinetics of therapeutic gene induction are slower at this time point than the kinetics of muscle damage. Beyond 6 weeks, the rate of muscle damage subsides and so this may not be as much of an issue when injected vectors at later time points.




Figure 1. Dose-response curve for rAAVrh74.MCK.GALGT2 and rAAVrh74.MHCK7.GALGT2 treatment. Wild type (WT), Cmah^{-/-}, mdx or Cmah^{-/-}mdx mice were given an intramuscular injection of AAV as indicated in the TA/EDL muscle. Muscles were analyzed for CT glycan overexpression 12 weeks after treatment. Errors are standard errors of the mean for n=10 animals per condition. vg : vector genomes. Statistical comparisons were done by ANOVA with post-hoc t test. *P<0.05, **P<0.01, ***P<0.001.

We took advantage of this finding to see if we could understand something about the kinetics of GALGT2's therapeutic mechanism in mdx skeletal muscle. As the principal target of GALGT2 glycosylation is α dystroglycan, and as α dystroglycan is reduced and destabilized in mdx muscles, and as we have previously shown that overexpression of dystroglycan does not ameliorate disease in mdx muscles, we co-injected identical doses of human dystroglycan (DAG1) and human GALGT2 using the MCK promoter in mdx muscles at 2 weeks and analyzed these at 3 months (Figure 2). Here, we now accelerated the therapeutic effects of GALGT2

overexpression, seeing 60% of the muscle transduced with CT glycan by a dose of 5×10^{11} vg. These data strongly suggest that GALGT2 is indeed therapeutic in mdx muscles, even at 2 weeks, but that the kinetics of gene expression do not allow for that effect to be seen when the single gene is injected at 3 months post-infection.




Figure 2. Co-injection of equivalent doses of dystroglycan (DAG1) and GALGT2 driven by the MHCK7 promoter. Errors are SD for n=3 per group. ***P<0.001

rAAVrh74.MHCK7.GALGT2 injection into mdx muscles at 2-3 weeks of age with analysis of CT glycan expression at 3 months post-treatment showed very low levels of sustained muscle transduction, however, co-injection of rAAVrh74.MHCK7.GALGT2 with an equivalent dose of rAAVrh74.MHCK7.DAG1 allowed for sustained GALGT2 induction of glycosylation. As

a dystroglycan is the principal target for GALGT2 and as a dystroglycan is down-regulated in mdx muscles, this suggest that the reduced dystroglycan expression in mdx muscles, coupled with the 3 week time for maximal gene expression induced by a single-stranded AAV GALGT2 vector⁴, did not allow GALGT2 to be therapeutic in the 3-6 week window in mdx muscles, a time at which severe muscle turnover occurs⁹.

We analyzed mRNA expression in all muscles where CT glycan overexpression was significant (all WT and *Cmah*^{-/-} muscles) to compare MCK and MHCK7 promoter induction of GALGT2 gene expression (Fig. 3). As expected based on the glycosylation data shown in Figure 1, MHCK7 promoter induced a statistically significant increased in GALGT2 gene expression compared to MCK promoter in both WT and *Cmah*^{-/-} muscles at all doses used.





Figure 3. qRT-PCR measurement of induction of GALGT2 gene expression by rAAVrh74.MCK.GALGT2 and rAAVrh74.MHCK7.GALGT2 in Wild type (WT) and *Cmah*^{-/-} skeletal muscles. Errors are SEM for n=10 per group. *P<0.05, **P<0.01, *P<0.001**

Figure 4 shows the relationship between GALGT2 mRNA induction and the percentage of myofibers overexpressing CT glycan for all experiments for WT and *Cmah^{-/-}* mice. As most doses saturated CT glycan in muscles, this allowed for us to take the left-most portion of this curve and determine whether there was a threshold of GALGT2 mRNA induction required to saturate CT glycan expression. While not the most beautiful line, this data suggests that a 430-fold increase in GALGT2 mRNA expression should be competent to induce near saturating levels of CT glycan overexpression. Such threshold data will be important when GALGT2 is injected IM in DMD patients, as we can measure the extent of mRNA overexpression and determine the level of CT glycan overexpression is what we would expect based on this work in



the mouse

Figure 4. Scatter plot comparing level of GALGT2 mRNA induction to the percentage of myofibers overexpressing CT glycan. Open circles indicate muscle injected with various doses of rAAVrh74.MCK.GALGT2, closed circles indicated muscles injected with various doses of rAAVrh74.MHCK7.GALGT2.

We have also measured the amount of vector DNA present in all of the muscles shown in Figure 1 and this is shown in Figure 5. qPCR was used to quantify vector DNA compared to a standard curve of plasmid. These data show that the number of vector genomes of gene therapy injected for rAAVrh74.MCK.GALGT2 and rAAVrh74.MHCK7.GALGT2 were roughly equivalent at each dose given. Therefore, changes in gene expression and functional glycosylation for the MHCK7 promoter are due to the action of the promoter in stimulating GALGT2 gene transcription.




Figure 5. Distribution of Vector genomes in injected skeletal muscles. WT and *Cmah*^{-/-} mouse muscles injected with rAAVrh74.MCK.GALGT2 or rAAVrh74.MHCK7.GALGT2 were compared for vector genomes of AAV DNA, per microgram of genomic DNA. Errors are SEM for n=10 samples per condition, each measured in duplicate.

With the assistance of our qualified optional collaborator, Dr. Paul Janssen, we were able to measure changes in specific maximal tetanic force of isolated EDL muscles, measured *ex vivo*, after 3 months of therapy with either rAAVrh74.MCK.GALGT2 or rAAVrh74.MHCK7.GALGT2. Here, we show changes in specific force that occurred in wild type and *Cmah^{-/-}* muscles when the muscles were saturated for GALGT2 overexpression at the 5×10^{11} vg dose.




Figure 6. Percentage change in specific force after GALGT2 treatment of wild type (WT) and *Cmah^{-/-}* skeletal muscles. High dose rAAV.MCK.GALGT2 and rAAV.MHCK7.GALGT2 in some cases led to increased specific force after 12 weeks administration in the extensor digitorum longus muscle measured *ex vivo*. Errors are SEM for n=10 muscles per condition.

In addition to completing milestones 1 and 2, we have begun dosing animals for milestone 3, including mdx and *Cmah^{-/-}*mdx animals at day 1 (3 each).

Last, we would note that we have accomplished a major milestones in our transition plan to move rAAVrh74.MCK.GALGT2 to a clinical trial for DMD. We have filed an application for use of rAAVrh74.MCK.GALGT2 with the Recombinant DNA Advisory Committee (RAC) at the NIH. RAC met on November 1, 2013 and approved the proposal without further comment. We have now also completed in-life GLP biodistribution and toxicology studies for IM and IA delivery of rAAVrh74.MCK.GALGT2. This report is certified and was included with an IND application to the FDA for a Phase 1 DMD clinical trial on September 23, 2014. The IND, 16175, was approved on October 17 and includes the IM portion of the phase I clinical trial. The data supporting an IA trial is included in this IND, but an amendment will be needed to proceed to that portion of the trial. Last, through other sources, we have obtained funds to begin cGMP clinical manufacturing of rAAVrh74.MCK.GALGT2 and that manufacturing process has begun now at the cGMP AAV Manufacturing facility at Nationwide Children's Hospital.

Key Research Accomplishments:

1. Completion of the study demonstrating human GALGT2 overexpression is more potent in mouse muscles when the Cmah gene, which is normally absent in humans but is expressed in mice, is deleted. This deletion better mimics the sialic acid substrates found in human muscle, suggesting that the human GALGT2 gene has more activity when the sialic acid substrates available mimic those found in humans.
2. Completion of the study demonstrating that MHCK7 promoter drives stronger GALGT2 expression than the MCK promoter in mouse skeletal muscle and

would therefore be more optimal for use in patients. This suggests that MHCK7 may be useful as a second generation promoter for GALGT2 gene therapy studies.

3. Demonstration that co-injection of dystroglycan with GALGT2 in mdx mice leads to higher levels of GALGT2 induced glycosylation. This suggest that lack of expression at two weeks is due to down-regulation of dystroglycan in mdx muscles such that GALGT2 glycosylation of α dystroglycan cannot be achieved prior to the onset of massive muscle degeneration in the 3-6 week time period.
4. Review and approval of rAAVrh74.MCK.GALGT2 clinical study by the Recombinant DNA Advisory Committee (RAC) of the NIH.
5. Completion of in-life cGMP biodistribution and toxicology studies for planned clinical trial for IM and IA delivery of rAAVrh74.MCK.GALGT2 in DMD patients.
6. Filing of IND with the FDA for use of rAAVrh74.MCK.GALGT2 in DMD patients.
7. Approval of IND (16175) for Phase 1 DMD clinical trial.

Reportable Outcomes:

1. DOD acknowledged in two presentations given by the PI this past year.
2. Data from this grant was used to support two grants submitted to the NIH.
3. Data from this grant was used to support the IND filing to the FDA for rAAVrh74.MCK.GALGT2 therapy, which was approved in October of 2014.

Conclusion: We have made excellent progress in Year 2 of this 3-year award, having now completed the milestones for Year 1 and Year 2. We have demonstrated that

humanizing mouse sialic acids allows the human GALGT2 gene to be more potent. This suggests that the minimally effective dose reported in the mouse for our IND application will be above or at the level we might expect in human muscle. We have demonstrated that the MHCK7 promoter drives stronger GALGT2 expression than the MCK promoter. This suggests that the use of the MHCK7 promoter may be more efficacious than the currently planned MCK promoter in patient trials for DMD. We have identified the level of mRNA overexpression required of GALGT2 to saturate muscle expression of the CT glycan. We have also demonstrated that co-expression of GALGT2 with dystroglycan drives better glycosylation at early time points in mdx muscles. In our transition plan, we have met three major milestones for rAAVrh74.MCK.GALGT2, having passed review by RAC, having completed and certified in-life GLP biodistribution and toxicology safety studies, and having filed and obtained an IND (16175) from the FDA for use of rAAVrh74.MCK.GALGT2 in DMD patients.

References:

1. Martin, P.T., *et al.* Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. *Am J Physiol Cell Physiol* **296**, C476-488 (2009).
2. Nguyen, H.H., Jayasinha, V., Xia, B., Hoyte, K. & Martin, P.T. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. *Proc Natl Acad Sci U S A* **99**, 5616-5621 (2002).
3. Xu, R., Camboni, M. & Martin, P.T. Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. *Neuromuscul Disord* **17**, 209-220 (2007).
4. Xu, R., Chandrasekharan, K., Yoon, J.H., Camboni, M. & Martin, P.T. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. *Am J Pathol* **171**, 181-199 (2007).

5. Xu, R., DeVries, S., Camboni, M. & Martin, P.T. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. *Am J Pathol* **175**, 235-247 (2009).
6. Chandrasekharan, K., *et al.* A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. *Sci Transl Med* **2**, 42ra54 (2010).
7. Smith, P.L. & Lowe, J.B. Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. *J Biol Chem* **269**, 15162-15171 (1994).
8. Salva, M.Z., *et al.* Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. *Mol Ther* **15**, 320-329 (2007).
9. De la Porte, S., Morin, S. & Koenig, J. Characteristics of skeletal muscle in mdx mutant mice. *Int Rev Cytol* **191**, 99-148 (1999).